The Herpevac Trial for Women: Sequence Analysis of Glycoproteins from Viruses Obtained from Infected Subjects.

Miguel A Minaya

Maria Korom
George Washington University

Hong Wang

Robert B Belshe

Lynda A Morrison

Follow this and additional works at: http://hsrchimelfarb.gwu.edu/smhs_microbio_facpubs

Part of the Medical Immunology Commons, Medical Microbiology Commons, and the Tropical Medicine Commons

APA Citation

Minaya, M., Korom, M., Wang, H., Belshe, R., & Morrison, L. (2017). The Herpevac Trial for Women: Sequence Analysis of Glycoproteins from Viruses Obtained from Infected Subjects. PLoS One, 12 (4). http://dx.doi.org/10.1371/journal.pone.0176687
RESEARCH ARTICLE

The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects

Miguel A. Minaya1, Maria Korom1a, Hong Wang1b, Robert B. Belshe2, Lynda A. Morrison1,2*

1 Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America

a Current address: Department of Microbiology, Immunology and Tropical Diseases, The George Washington University School of Medicine, Washington, DC, United States of America
b Current address: Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America

* morrisla@slu.edu

Abstract

The Herpevac Trial for Women revealed that three dose HSV-2 gD vaccine was 58% protective against culture-positive HSV-1 genital disease, but it was not protective against HSV-2 infection or disease. To determine whether vaccine-induced immune responses had selected for a particular gD sequence in strains infecting vaccine recipients compared with viruses infecting control subjects, genetic sequencing studies were carried out on viruses isolated from subjects infected with HSV-1 or HSV-2. We identified naturally occurring variants among the gD sequences obtained from 83 infected subjects. Unique or low frequency amino acid substitutions in the ectodomain of gD were found in 6 of 39 HSV-1-infected subjects and in 7 of 44 HSV-2-infected subjects. However, no consistent amino acid change was identified in isolates from gD-2 vaccine recipients compared with infected placebo recipients. gC and gE surround and partially shield gD from neutralizing antibody, and gB also participates closely in the viral entry process. Therefore, these genes were sequenced from a number of isolates to assess whether sequence variation may alter protein conformation and influence the virus strain’s capacity to be neutralized by vaccine-induced antibody. gC and gE genes sequenced from HSV-1-infected subjects showed more variability than their HSV-2 counterparts. The gB sequences of HSV-1 oral isolates resembled each other more than they did gB sequences from genital isolates. Overall, however, comparison of glycoprotein sequences of viral isolates obtained from infected subjects did not reveal any singular selective pressure on the viral cell attachment protein or surrounding glycoproteins due to administration of gD-2 vaccine.
Introduction

Herpes simplex virus 1 (HSV-1) and HSV-2 are highly related human herpesviruses. Their 152 to 155 kb colinear genomes share 87% amino acid sequence identity and encode 84 proteins [1]. Both viruses also share structural features including an icosahedral capsid, a dense layer of tegument proteins, and a host cell-derived lipid envelope studded with viral glycoproteins important in cell attachment and penetration. Historically HSV-1 caused most oral infections and HSV-2 most genital infections; however, HSV-1 is now responsible for a majority of genital infections [2–7]. Over 400 million people world-wide are thought to have genital HSV infections [8]. In addition to the direct impacts of HSV on the physical and psychosocial health of infected individuals, women can pass the virus to their babies during birth, resulting in severe and often lethal disease [9]. Previous infection with HSV also increases the risk of co-infection with HIV [10,11], and infectious HIV is shed from HSV-2 genital ulcers [12], making HIV transmission more likely [13]. The ability to control HSV infections would have a wide-ranging positive impact on public health.

The lifecycle of HSV-1 and HSV-2 alternates between lytic infectious and latent phases. The viruses typically enter the body through mucosal epithelium or abraded skin. Replication in epithelial cells leads to lysis which rapidly puts virus in contact with nerve termini innervating the site of infection. Intra-axonal transport conveys the virus to nerve cell bodies in sensory ganglia. Here the virus establishes a latent infection that persists for the lifetime of the infected individual. Periods of viral reactivation permit recurrent virus shedding in the periphery and re-infection of the epithelium, thus perpetuating the lytic-latent cycle and providing an opportunity for transmission. Nine viral glycoproteins play significant and in some cases essential roles in the virus lifecycle. Glycoprotein D (gD) interacts with the cellular receptors nectin 1, HVEM, and also nectin 2 in the case of HSV-2 [14]. Conformational changes triggered in gD by receptor binding lead to interaction of gD with gH/gL [15]. Subsequent interaction of activated gH/gL with gB stimulates gB fusogenic activity [16–18]. Thus, gD binding initiates several interactions critical for successful HSV infection.

Glycoproteins gC and gE play strategic roles in HSV immune evasion. gC binds the C3b component of complement to prevent complement activation and virolysis [19,20]. gE in complex with gI acts as an immunoglobulin Fc receptor, preventing antibody-mediated viral neutralization [21–23], and facilitating clearance of viral antigens and antiviral antibody from the cell surface [24]. gC and gE also surround and partially shield gD from neutralizing antibody attack that could interfere with virus entry [25].

HSV-1 and HSV-2 have a relatively low mutation rate due to the proofreading activity of their DNA polymerases [1]. Nonetheless, sequence diversity has been noted in certain glycoproteins [26–29]. Considered on a global scale, HSV glycoprotein sequence diversity increases with geographic distance [28]. Development of a vaccine that can effectively counter this breadth of diversity among strains is a significant challenge. Attempts to prevent HSV infection to date have focused primarily on the use of viral glycoprotein subunit vaccines. A vaccine composed of gD adjuvanted with alum and 3-0-deacylated monophosphoryl lipid A (ASO4) showed promise in early vaccine trials [30], prompting a large, multicenter Phase III trial, the Herpevac Trial for Women [31]. A total of 8,323 young adult women who were seronegative for both HSV-1 and HSV-2 received three doses of the ectodomain (amino acids 26–309) of HSV-2 gD in adjuvant or a control hepatitis A virus (HAV) vaccine. The gD-2 vaccine provided 58% protection against HSV-1 culture positive disease but did not protect against HSV-2. How HSV-2 successfully evaded the vaccine-induced immune response has been a central question in understanding the outcome of the trial.
Results from the Herpevac Trial for Women indicated protection was associated with antibody titer but not CD4 or CD8 T cells against HSV-1, and therefore neutralizing antibodies evoked by vaccination have been considered critical to successfully preventing HSV infection [32]. Whether neutralizing antibodies among the antibodies measured by ELISA positively correlate with protection is the subject of an ongoing study. Mechanisms of virus neutralization could involve blocking gD’s nectin-1 or HVEM binding domains [33–38], or preventing gD association with gH/gL [37]. Antibody escape variants have been noted for many viruses. Thus, vaccine-induced antibody responses could limit infection to particular strains whose glycoprotein sequences facilitate immune evasion. Pre-existing antibody may also be a driving force for selection of a variant with increased fitness within a vaccinated, infected individual. We therefore determined whether glycoprotein sequences differed between virus isolates from gD-2 vaccine recipients in the Herpevac Trial who became infected and isolates from infected, control-vaccinated subjects.

Materials and methods

Cells and viruses

Vero (African green monkey kidney) cells were originally acquired from the laboratory of David Knipe and were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 3% newborn calf and 3% bovine growth sera, 100 IU/ml penicillin and 0.1 mg/ml streptomycin (1x P/S). HSV-1 and HSV-2 swab isolates in transport medium collected during the Herpevac Trial for Women were thawed and 100 μl were inoculated onto Vero cell monolayers in T75 flasks. Monolayers were incubated until cytopathic effect reached 100%, and cell lysate stocks of the isolates were prepared as previously described [39]. The study was approved by the Saint Louis University Institutional Review Board (IRB number 24706) and subjects provided written consent to future use of their samples.

DNA isolation and sequencing

Viral DNA was purified from a portion of each virus lysate using QIAamp DNA Mini kit (Qiagen, Valencia, CA) according to the manufacturer’s recommendations. Glycoprotein genes were PCR-amplified using strain-specific primers (Table 1). Amplification reactions used a reaction mixture containing 0.75 μl of forward and reverse primer (10 mM), 2.5 μl 10X AccuPrime™ Pfx Reaction Mix (Invitrogen), 2.5 μl Betaine solution (5M) (Sigma), 2 μl MgCl₂ (50mM), 1.5 μl DMSO, 0.5 μl Taq DNA Polymerase, 2 to 4 μl of template DNA in a total reaction vol of 25 μl. The amplification parameters consisted of an initial denaturing step of 2 min at 95˚C, followed by 39 cycles of 20 sec denaturing at 95˚C, 30 sec annealing at primer-specific temperature, and 3 min extension at 68˚C, followed by a final extension step of 5 min at 68˚C. DNA products were purified by agarose gel electrophoresis and extracted using a PureLink Quick Gel Extraction kit (Invitrogen, Grand Island, NY). Sanger sequencing of purified PCR products was conducted by GeneWiz, Inc. (South Plainfield, NJ).

Sequence analyses

As a quality control measure, each chromatogram was visually inspected for miscalled nucleotides and overlapping peaks that could indicate a mixed population. Complementary strands were assembled and verified using Clone Manager 9 Professional Edition. The obtained sequences were aligned and adjusted manually using MEGA (v7.0.14) [40]. Nucleic acid sequences of glycoproteins from HSV-1 isolates were aligned to reference sequences from HSV-1 strain KOS (Table 2) [41]. Nucleic acid sequences containing gD coding regions of
HSV-2 isolates were aligned to reference sequences from HSV-2 strain G [42] or SD90e [43]. SD90e furnished the reference sequences for the remaining glycoproteins. gD sequences from HSV-1 strains F [42], 17 [44], and McKrae [45], and HSV-2 strains 186 [46] and 333 [47] were also included in some comparisons. The percentage of polymorphic nucleotides and pairwise comparison to the reference sequence [transition/transversion (T/V) ratio] for each glycoprotein (gB, gC, gD and gE) of HSV-1 and HSV-2 strains were assessed using PAUP 4.0 beta10 [48]. The collection of isolates in this study was compared with verified primary clinical isolates previously deposited in GenBank. Because of the low numbers of polymorphisms per sequence, the Ts/Tv ratio is expressed as the sum of the transitions across the isolates divided by the sum of the transversions. GenBank accession numbers for all the glycoprotein sequences obtained herein and previously sequenced corresponding genes of primary isolates are listed in S1 Table. Only nucleotides encompassing the ORF of each protein were considered, excluding INDELs [49]. Two groups of strains were used: the newly sequenced strains

Table 1. Primers used for amplification of HSVgB, gC, gD, and gE genes.

| Glycoprotein | Name   | Genome location | Sequence 5' to 3' |
|--------------|--------|-----------------|-------------------|
| HSV-1 gB     | gB1-FWD| 52616           | GCCGATTTTGTTCGTCTC |
|              | gB1-REV| 56125           | CGTCASCCGATTTTGCAG |
| HSV-1 gC     | gC1-FWD| 95768           | TCCGAGTTTGTCTGTA TG |
|              | gC1-REV| 98149           | GTTAACTCGTGTCCATCGCCTGTC |
| HSV-1 gD     | gD1-FWD| 138074          | GCGGTGTCACATTATGCCTCATAC |
|              | gD1-REV| 139758          | CGGCGTCCACAAATGGATTTTGATACCGAG |
| HSV-1 gE     | gE1-FWD| 140831          | ACCGCGTCACTGAGTG |
|              | gE1-REV| 143263          | CGCTTTTCGAGTAGTGG |
| HSV-2 gB     | gB2-FWD| 53108           | ACTCGCGCGCTTCATAGG |
|              | gB2-REV| 56589           | GGGAAAGTGCGCGGAAGTAC |
| HSV-2 gC     | gC2-FWD| 96855           | AGGCGGCCCCATCTGTTAGGGTATT |
|              | gC2-REV| 98691           | GCCATAGCACCCACCGCGGCTTTGATAT |
| HSV-2 gD     | gD2-FWD| 140944          | GGTGCGTCTCGTCAFAAG |
|              | gD2-REV| 142270          | TCCAAGTCCCCACACAAATAC |
| HSV-2 gE     | gE2-FWD| 143400          | GTCCACGCCATGCTGCTCTCTCATAAC |
|              | gE2-REV| 145681          | ACGGCAGGCCAGGTGACAAATGG |

* Nucleotide position in the complete genome of HSV-1 (GenBank accession #JQ673480) or HSV-2 (JN561323).

https://doi.org/10.1371/journal.pone.0176687.t001

Table 2. Number of subjects (isolates).

| Infection | Vaccine | HSV | HAV |
|-----------|---------|-----|-----|
| HSV-1     | Oral    | 6 (7) | 3 (3) |
|           | Genital | 12 (13) | 16 (18) |
|           | Rectal  | 2 (2)  | |
|           | Total   | 18 (20) | 21 (23) | 39 (43) |
| HSV-2     | Oral    | 0 (2)  | |
|           | Genital | 29 (35) | 12 (16) |
|           | Rectal  | 2 (3)  | |
|           | Buttock | 1 (1)  | |
|           | Total   | 32 (41) | 12 (16) | 44 (57) |
|           |         |       | 83 (100) |

https://doi.org/10.1371/journal.pone.0176687.t002
presented in this research, and verified low passage clinical strains previously uploaded to GenBank (S1 Table) [50]. Variation of nucleotides across the alignment was calculated using the HSV-1 KOS reference strain for all HSV-1 isolates, the HSV-2 strain G for gD of HSV-2 samples, and the HSV-2 strain SD90e for HSV-2 gB, gC and gE.

The frequencies of non-synonymous (dN), and synonymous (dS) substitutions were calculated based on the codon-aligned nucleotide sequences in a data set that included all gD sequences from 39 HSV-1 infected subjects and 44 HSV-2 infected subjects. dN/dS ratios were calculated for HSV-1 and HSV-2 gB, gC and gE based on sequences determined for a subset of isolates. These calculations were performed using the SNAP (Synonymous Non-synonymous Analysis Program v2.1.1) website [51], which determines the number of non-synonymous vs. synonymous base substitutions for all pairwise comparisons of sequences in an alignment. To investigate positive selection on a site-by-site basis we used an agreement-based inference that included five methods: Fixed Effects Likelihood (FEL), Internal Fixed Effects Likelihood (IFEL), Single-Likelihood Ancestor Counting (SLAC), Mixed Effects Model of Evolution (MEME), and Fast Unbiased Bayesian Approximation (FUBAR) (DataMonkey software package; [52,53]). Following the criteria of Lamers et al. [28], positive selection was considered likely when at least three of these methods indicated positive selection at a particular coding position.

The SLAC method, a substantially modified and improved derivative of the Suzuki-Gojobori method [54], involves counting the number of dN and dS changes and testing whether dN is significantly different from dS. The FEL method [55] incorporates models of nucleotide substitution bias and variation in both non-synonymous and synonymous substitution and thus estimates the dN and dS rates at each site. The IFEL method [56] infers whether the instantaneous dS site rate is lower than the instantaneous dN site rate. IFEL differs in that it is used to determine whether selection is occurring at the population level by investigating sitewise selection on internal branches of a phylogenetic tree [56]. The MEME method [57] detects adaptive evolution and can identify instances of positive selection affecting individual codon positions. Finally, the FUBAR method [58] detects positively selected codon positions using a Bayesian approximation. A Markov Chain Monte Carlo routine used in this method allows flexible prior specification with no parametric constraints on the prior shape, and visualizes Bayesian inference for each nucleotide. The cutoff P value used in FEL, IFEL, SLAC and MEME was 0.1, while the value used in FUBAR was 0.9 as recommended in DataMonkey.

**Statistical analyses**

The proportion of sequences from gD-2 vaccine versus control vaccine recipients which contained ectodomain polymorphisms was compared using the Fisher exact test. Statistical significance of the dN/dS ratios of sequences from gD-2 vaccine recipients and control vaccine recipients was determined by an unpaired t test.

**Results**

Genetic sequencing studies were carried out on gD of viruses isolated from women who became infected with HSV-1 or HSV-2 during the trial to establish whether amino acid variants of the cell attachment protein correlated with successful infection. Subjects had received up to three doses of either HSV gD-2 vaccine in adjuvant or HAV vaccine as a control vaccine. A total of 100 primary or recurrent isolates were obtained from 39 subjects infected with HSV-1 and 44 subjects infected with HSV-2 (Table 2). Of the 39 HSV-1-infected subjects, 30 (77%) had genital (or rectal) infections and 9 (23%) had oral infections. A larger proportion of the culture-positive HSV-1 genital infections occurred in subjects receiving control vaccine than
gD-2 vaccine [18 (2 were rectal) v. 12 subjects; 60% v. 40%]. Nearly all culture-positive infections with HSV-2 occurred in the genital or rectal mucosa, 12 in control vaccine recipients and 31 in gD-2 vaccine recipients. One of the gD-2 vaccine recipients acquired a buttock infection with HSV-2, and two experienced oral as well as genital infections. Isolates obtained from subjects with recurrent disease in the months after primary infection were also sequenced.

**gD sequences**

Forty-three HSV-1 gD gene sequences were determined for primary or recurrent isolates from the 39 HSV-1-infected subjects, and were compared with gD from HSV-1 strain KOS as a reference sequence. Ten of the 39 subjects’ gD sequences were identical to HSV-1 KOS even at the nucleic acid level, and 14 at the amino acid level. Nucleotide polymorphisms in other gD sequences were scattered throughout the open reading frame, but only 7 non-synonymous changes were observed (Fig 1B). Two of these, A4T and A10V, lie within the leader sequence cleaved to form the mature protein. One amino acid sequence variant within the ectodomain may represent a naturally occurring polymorphism. Specifically, an E142D substitution in 5 subjects’ gD sequence also appeared in a patient isolate in GenBank, E03. Notably, two unique amino acid changes were also observed: L47H was found in one gD-2 vaccine recipient, and L355M in the transmembrane domain was found in another gD-2 vaccine recipient. Twenty of the 39 subjects had H365R and R369Q substitutions in the cytoplasmic domain that are also present in laboratory strains F, 17 and McKrae. Interestingly, one subject’s isolate contained both the A4T and H365R/R369Q substitutions, suggesting a possible recombination event. None of these polymorphisms was associated with a particular route of infection. In all gD sequences bearing nucleotide polymorphisms, the same nucleotide was almost always substituted at a given position. The largest number of nucleotide changes per gD sequence was 11, with an average of 3.7 per subject (0.33%). These resulted in 3 or fewer amino acid substitutions per subject, with an average of only 0.23 non-synonymous changes per subject in the region spanned by the vaccine.

Fifty-seven gD gene sequences were determined for primary or recurrent isolates from the 44 HSV-2-infected subjects, then were compared with gD from HSV-2 strain G (from which the vaccine was derived) as a reference sequence. The gD sequence of two other HSV-2 laboratory strains, 333 and 186, and the field isolate SD90e were also compared. Only eight non-synonymous amino acid substitutions were observed among the gD sequences obtained from HSV-2-infected subjects (Fig 1C). One of these changes, G2W, occurred in the leader sequence. Isolates from 4 other HSV-2-infected subjects contained unique amino acid change(s) in the gD ectodomain: A37V and T274I (occurring together), D284A, or V327I. In addition, 4 of the 44 subjects had a V169A substitution which was also found in a gD sequence previously submitted to GenBank, Pt10, suggesting that it is a naturally occurring polymorphism. A347T and A353V substitutions were found in the transmembrane domain of gD. The former was unique, whereas 39 of 44 isolates had the A353V substitution which was also present in the laboratory strains 186 and 333. The largest number of nucleotide changes in an HSV-2 gD sequence was 5, with an average of only 1.16 synonymous substitutions and 1.09 non-synonymous substitutions per subject (total = 0.18%). These resulted in 3 or fewer amino acid substitutions in the gD sequence of a given subject, and within the region spanned by the vaccine an average of only 0.21 non-synonymous changes occurred per subject. When oral and genital infections with HSV-2 occurred within the same individual, the gD sequences were identical.

In summary, 7 infrequent polymorphisms were found in the gD ectodomain of isolates from 13 subjects, 6 subjects infected with HSV-1 and 7 with HSV-2. The two changes in HSV-1-infected subjects (L47H and E142D) and 4 of the 5 in HSV-2-infected subjects (A37V,
V169A, T274I and D284A) occurred in the portion of the ectodomain spanned by the vaccine. Ten gD-2-vaccinated subjects became infected with viruses that had ectodomain polymorphisms compared with only 3 of the control vaccine recipients, but this difference was not statistically significant (P = 0.222). None of the gD sequences from 4 recurrent isolates obtained from among the 39 HSV-1-infected subjects and 13 recurrent isolates from among the 44 HSV-2-infected subjects differed from the subject’s primary isolate at the amino acid or nucleotide levels, consistent with another recent report [59].
Sequences of glycoproteins C and E

gC and gE surround and partially shield gD from neutralizing antibodies that could interfere with gD receptor interaction or its association with gH/gL [25]. We therefore sequenced these genes from several isolates to determine whether sequence variation may alter protein conformation and influence the virus strain’s capacity to be neutralized by vaccine-induced antibody. Eight HSV-1 gC genes were sequenced from subjects’ isolates, half from gD-2 vaccine recipients and half from those receiving control vaccine. Five gC amino acid sequences closely resembled the reference strain KOS (Fig 2A). The last three HSV-1 gC sequences contained numerous amino acid substitutions in a similar pattern, primarily in the N-terminal third of the molecule. Nucleotide changes were more numerous overall than with HSV-1 gD, ranging from 1 to 19 per sequence (average 11.1, 0.7%). Of six HSV-2 gC genes sequenced, 5 contained only two amino acid substitutions compared with the field isolate SD90e (Fig 2B). Divergence at the nucleotide level was also very low for 5 of 6 isolates, with 0 to 4 differences (average 2, 0.14%). However, the sixth HSV-2 gC sequence contained 8 amino acid substitutions relative to gC of SD90e, and 11 nucleotide substitutions (divergence of 0.76%). Overall HSV-2 gC nucleotide divergence was thus 0.21%.

gE sequences were also determined for the same subset of HSV-1 and HSV-2 isolates. Two HSV-1 gE amino acid sequences were identical to KOS, and three more were very similar to KOS (Fig 3A). The other three gE amino acid sequences resembled each other, but differed substantially from KOS. At the nucleotide level, the number of substitutions ranged from 1 to 27 (average 0.55%). Interestingly, the three HSV-1 isolates with gE amino acid sequences most

Fig 2. gC amino acid sequences of isolates from the Herpevac Trial. The UL44 gene encoding gC was sequenced from selected subjects' isolates and aligned to reference sequences, then translated. Amino acid substitutions are diagramed for A) gC from HSV-1-infected subjects, B) gC from HSV-2-infected subjects. Numbers to the right of each sequence representation indicate the number of subjects sharing the amino acid sequence. C, control vaccinated subject; V, gD-2 vaccinated subject. The triangle represents a deletion of one amino acid.

https://doi.org/10.1371/journal.pone.0176687.g002
divergent from KOS also had the most divergent gC sequences. In contrast to HSV-1 gE, the six HSV-2 gE sequences had very few polymorphic residues compared with gE of SD90e (Fig 3B). Nucleic acid substitutions were also rare, ranging from 0 to 3 (average 0.12%). No correlations existed between gC or gE sequences and subjects’ route of infection or receipt of gD-2 vaccine (data not shown).

**gB sequences**

Because gB and gD each interact with the gH/gL complex during the entry process [60], conformational changes accompanying gB sequence alterations could conceivably influence the capacity of vaccine-induced antibody to access gD. We therefore sequenced the gB genes of the same subset of 8 HSV-1 and 6 HSV-2 isolates. Focusing on the ectodomain of the mature gB protein, 3 gB amino acid sequences of HSV-1 genital tract isolates had a V553A substitution but were otherwise identical to the KOS reference sequence (Fig 4A). An additional sequence bore 3 substitutions in the N-terminus and a unique S473N substitution. Nearly all polymorphic residues in the remaining 4 isolates were located within the N-terminal 79 amino acids of gB; notably, several of the substitutions were to proline residues and all 4 were oral isolates. All nucleotide sequences of gB from HSV-1 isolates, however, contained numerous (17 to 22) nucleotide changes in the ORF compared with KOS (average 0.70%). HSV-2 gB amino acid sequences from 5 out of 6 subjects also varied primarily in the same N-terminal portion as the HSV-1 isolates (Fig 4B), with an average of 3 substitutions per subject. Interestingly, most HSV-2 gB nucleotide changes were non-synonymous; however, no correlation between pattern of amino acid substitutions and vaccination with gD-2 or control vaccine was observed. HSV-2 gB nucleotide differences relative to SD90e ranged from 4 to 7 per sequence (average 0.20%). Table 3 summarizes the nucleotide variation among glycoprotein sequences obtained. The rate of
polymorphisms when compared with sequences already deposited in GenBank was similar for all glycoproteins except for HSV-1 gD, whose sequences were less polymorphic in our study. The transition/transversion (T\_S/T\_V) ratio, however, was lower for HSV-1 gD in our study than previously deposited sequences (Table 3), indicating a greater proportion of the polymorphisms were transversions. Overall, the lowest (T\_S/T\_V) ratios occurred in HSV-2 gC and gE.

It was of interest to determine whether the vaccine may have placed immune selective pressure on infecting viruses such that the variant glycoprotein sequences most apt to evade preexisting antibody to the gD ectodomain emerged. The dN/dS ratio measures the relative importance of selection as a driving force for amino acid changes in a coding region. We therefore determined this ratio for each of the glycoprotein sets. As shown in Fig 5 and S2 Table, most of the glycoproteins had dN/dS <1, indicating purifying selection pressure. The gD sequences of both HSV-1 and HSV-2 were highly constrained, as might be expected of a viral cell attachment protein. Higher dN/dS ratios were found for the HSV-2 glycoproteins, but only HSV-2 gB had dN/dS >1, suggesting positive selection. Even so, several methods of analysis failed to consistently identify positively selected residues (S3 Table).

Discussion
The gD sequences of viral isolates derived from 83 women who became infected during the phase 3 Herpevac Trial were determined. Thirty-six of 44 HSV-2-infected subjects had gD
Table 3. Nucleotide sequence diversity in glycoproteins B, C, D and E among HSV-1 and HSV-2 primary isolates.

| Glycoprotein sequences | gB | gC | gD | gE |
|------------------------|----|----|----|----|
| **HSV-1**              |    |    |    |    |
| Newly sequenced GenBank| 8  | 22 | 8  | 72 |
| Newly sequenced GenBank| 39 | 24 | 8  | 27 |
| Number of sequences a |    |    |    |    |
| % polymorphic nt. b   | 0.70% | 0.80% | 0.70% | 0.80% |
| T<sub>S</sub> / T<sub>V</sub> ratio c | 1.88 | 2.44 | 2.54 | 1.14 |
| Avg. G+C content      | 66.46% | 66.47% | 68.20% | 68.19% |
| **HSV-2**              |    |    |    |    |
| Newly sequenced GenBank| 6  | 107| 6  | 5  |
| Newly sequenced GenBank| 44 | 49 | 6  | 41 |
| Number of sequences a |    |    |    |    |
| % polymorphic nt. b   | 0.20% | 0.30% | 0.21% | 0.19% |
| T<sub>S</sub> / T<sub>V</sub> ratio c | 2.11 | 1.76 | 8.06 | 13.00 |
| Avg. G+C content      | 67.06% | 67.09% | 70.56% | 70.53% |

<sup>a</sup> Number of verified glycoprotein sequences used in these comparisons of Herpevac Trial isolates and existing GenBank entries (S1 Table). Only nucleotides encompassing the ORF of each protein were considered.

<sup>b</sup> Average percentage of nucleotides (nt.) differing from HSV-1 reference sequence KOS (JQ673480) or HSV-2 reference strains G (KY933650) for gD or SD90e (JN561323) for the other glycoproteins. Positions in INDELs were excluded.

<sup>c</sup> Average Transition (T<sub>S</sub>) / Transversion (T<sub>V</sub>) ratio when compared with the HSV-1 reference sequence KOS or the HSV-2 reference strains G for gD or SD90e for the other glycoproteins. Positions in INDELs were excluded.

https://doi.org/10.1371/journal.pone.0176687.t003

Fig 5. dn/ds ratios for HSV-1 and HSV-2 glycoprotein gene sequences. Mean ratio of non-synonymous to synonymous evolutionary substitutions (dn/ds) within the U<sub>27</sub> (gB), U<sub>44</sub> (gC), U<sub>6</sub> (gD) and U<sub>8</sub> (gE) genes is shown for all HSV-1 and -2 strains sampled. The dn/ds ratio for all HSV-2 gD sequences from gD-2 vaccine recipients was not significantly different than control subjects (0.61 versus 0.53, P = 0.554 by unpaired t test).

https://doi.org/10.1371/journal.pone.0176687.g005
sequences with an A353V substitution in the transmembrane domain compared with HSV-2 strain G from which the vaccine was derived. However, amino acid 353 was not contained in the truncated gD-2 vaccine so an immune response to the vaccine could not have exerted selective pressure. Similarly, 21 of 39 subjects’ HSV-1 isolates had H365R plus R369Q polymorphisms in the transmembrane and cytoplasmic regions not present in the vaccine. An E142D substitution in the ectodomain of several HSV-1 isolates and V169A in several HSV-2 isolates may be naturally occurring polymorphisms because they were also noted in patients’ gD sequences previously submitted to GenBank. Evidence that all of the above-mentioned substitutions could be naturally occurring polymorphisms include 1) the fact that the same nucleotide was substituted at these polymorphic sites in almost all instances; 2) most changes had also been found in one or more reference sequences; and 3) V169A and A353V were also noted in HSV-2 gD sequences from HIV positive or negative individuals [29]. Inspection of chromatograms did not reveal any overlapping peaks, suggesting that other sequence variants, if present, occurred at very low frequency. In addition, we observed complete conservation of nucleotide sequences between primary and recurrent isolates from the same subject, suggesting polymorphic residues were not a response to immune selective pressure post-infection. Therefore, evolution of gD is very constrained and gD sequence variation is not an explanation for the observed lack of vaccine efficacy against HSV-2 [29,59].

Different faces of the gD glycoprotein determine its critical functions in HSV infection (Fig 1A) [14]. One face interacts with the cellular receptor, and another interacts with gH/gL, causing a conformational change that renders gB fusion-competent [37]. The gD receptor HVEM [61] is found on lymphocytes [62], and the receptor nectin-1 [63] is a component of epithelial adherens junctions [64]. HSV-1 can also utilize 3-O-sulfated heparin sulfate [65], and HSV-2 also utilizes nectin-2 [66]. Structural studies of gD bound to its receptor reveal displacement of the C terminus of the gD ectodomain, necessary for activating fusion via gH/gL and gB [15,67]. A V231W substitution in gD was found to mimic this displacement in the absence of receptor binding [68], and interestingly we observed one HSV-2 sequence with a V231I substitution. A37V and L47H are not residues directly involved in interaction with HVEM [69], and no residues in the N- or C-terminal extensions of gD known to interact with nectin-1 [70] are impacted by a substitution, as might be expected of viruses that had successfully infected subjects. Similarly, gD interactions with gH/gL [71] and gB [72] do not appear to be affected by any of the substitutions found in subjects’ isolates in the gD profusion domain. The A353V and A355M mutations lie within the gD transmembrane region and so are less likely to have affected gH/gL or gB interaction.

Point mutations that disrupt linear or discontinuous neutralizing antibody epitopes would permit escape from vaccine-elicited responses. The molecular interactions of one neutralizing antibody, E317, which binds a conformational epitope on gD have been solved by co-crystallization [36]. None of the amino acid changes in HSV-1 or HSV-2 gD sequences from Herpevac Trial subjects map to E317 contact residues. Linear epitopes on gD recognized by neutralizing antibody are represented by peptides 1–20, 10–29, 19–38, 262–281, and 280–316 [37,38]. A37V, which occurred in HSV-2 isolates of gD vaccine recipients who became infected, lies within linear epitope 1–20 (as numbered from the first amino acid after the signal sequence). The L47H mutation in one subject’s HSV-1 isolate lies within overlapping peptide 10–29, known to be recognized by patient sera [38]. Each of these substitutions could have contributed to immune evasion by preventing neutralizing antibody from binding and blocking the interaction of gD with its receptor [37]. Antibodies to this N-terminal region are found in the sera of HSV-1 and HSV-2-infected individuals [73,74], indicating this site is indeed immunogenic. However, the L47H and A37V mutations were unique among changes in single isolates and therefore could not have been a general cause of immune escape. It is possible that other
point mutations or polymorphisms in some of the isolates cause conformational changes in gD which disrupt antibody-gD interaction. It will be of interest to determine the relative level of neutralizing antibody in these subjects’ sera to address the hypothesis that one or more of these mutations could have allowed the virus to escape neutralization.

Other potential explanations exist for why a gD-specific immune response to vaccine could not prevent infection despite overt similarity in amino acid sequence of the ectodomain: First, conformation of a protein can affect the binding capacity of antibody molecules whose epitopes are dependent on tertiary structure. It is possible that the polypeptide used for the vaccination adopts a different conformation than the same sequence when contained within the full-length protein. In addition, chemical composition of the adjuvant could potentially affect gD conformation. Second, polymorphisms may exist in a minority of reads that would not be visible as overlapping peaks in the Sanger sequence traces; however, any such minor variants most likely could not have contributed appreciably to capacity of these viruses to infect vaccinated individuals. Third, we focused on polymorphisms in the ectodomain of gD, but approximately half of HSV-1 isolates contained variant H365R plus R369Q residues in the cytoplasmic of the gD molecule. Conceivably polymorphic residues in this region could affect recruitment of gD to rafts, interactions with other viral proteins in the infected cell membrane, or vesicular transport in neurons. Lastly, although T cell responses did not correlate with protection in the Herpevac Trial (32), alteration of a CD4 or CD8 T cell epitope in gD could conceivably have allowed virus to evade a vaccine-induced T cell response to gD in certain subjects. No amino acid substitutions occurred within known CD8 T cell epitopes presented by HLA-A’0201 [75]. However, isolates from four HSV-2-infected, Herpevac Trial subjects contained a polymorphism (V169A) in a known HLA-DR-restricted, CD4 T cell epitope [76]. Three of the four isolates were from gD vaccine recipients. Whether this polymorphism could have partially reduced the CD4 T cell response in select subject(s) with an appropriate HLA-DR haplotype is not yet known.

A quantitative measure of vaccine-mediated selection of virus variants that could potentially evade the gD-specific immune response would be a finding of a higher $dN/dS$ ratio for gD sequences from vaccine recipients compared with control-vaccinated subjects. Indeed, 8 out of the 10 individual HSV-2 gD sequences with $dN/dS > 1$ came from gD-vaccinated subjects ($P = 0.023$). However, the $dN/dS$ ratio for all HSV-2 gD sequences from gD-2 vaccine recipients was not significantly different than control subjects (0.61 versus 0.53, $P = 0.554$). In addition, the $dN/dS$ ratios for gD sequences from the HSV-1 and HSV-2 isolates (S2 Table) align with previously published ratios for the same genes [27,28,77]. Overall, these results do not strongly support a specific capacity of the vaccine-induced anti-gD response to select natural sequence variants.

We identified A353V as a major discriminator between strains similar to HSV-2 strain G gD and those similar to SD90e. In a comparison of 36 geographically disparate HSV-2 gD sequences, amino acid 353 of HSV-2 gD had been identified as undergoing positive selection by the iFEL method [28], and as a polymorphic residue by a third group [29]. In our data set, residue 353 was not flagged as undergoing positive selection by any of the 5 methods tested (S3 Table). Interestingly, in the subject isolates we tested, either H365/R369 or R365/Q369 always occur together in the gD sequence, suggesting co-selection of this amino acid pair.

Definition of a reference strain is an important consideration in sequence comparisons. Our survey of 100 isolates from 83 subjects suggests that for HSV-1 gD, the sequence of laboratory strain KOS most closely resembled a significant proportion of the isolates. gD of McKrae represented a majority of the remaining isolates (14 at the amino acid level and 4 at the nucleotide level) due to the presence of the H365R/R369Q variant. Interestingly, nucleotide changes underlying these variant amino acids are also associated with a synonymous a$>g$ substitution.
at position 963. Patterns of amino acid substitutions such as this variant cluster may be useful in epidemiological tracking, and also in assessing recombination frequency since the A4T substitution was negatively associated with the C-terminal cluster of substitutions. It has been argued that the South African strain SD90e should be used as the standard HSV-2 reference sequence [77]. Only 2 out of 44 subjects’ HSV-2 gD nucleotide sequences were identical to SD90e, and only 2 matched that of HG52 or strain G which was the source of the vaccine. However, SD90e contains nucleotides C733 and T1058 which characterize the majority of the 44 subjects’ gD sequences, and result in amino acid sequence identity with 27 of the 44 subjects. Greater identity with the South African strain than with the laboratory strain HG52 was also noted in HSV-2 gE and gB. Thus we chose SD90e as the reference sequence for HSV-2 gB, gC and gE.

Consideration of strain-dependent differences is also critical in vaccine design, as was demonstrated by the reduced capacity of dl5-29 to protect against South African strains compared to U.S. strains in a murine model [78]. For selection of a gD-based vaccine, our results suggest that the strain G ectodomain would adequately represent the ectodomain of most wild viruses since it was identical to 37 of 44 subjects’ gD ectodomains and to gD of SD90e.

Diversity among HSV-1 strains is described as greater than HSV-2 [79–81], and we found this to be true of the HSV-1 genes sampled here (Table 3). HSV-1 UL44 encoding gC was previously noted as among the most variable genes in the HSV-1 genome [27]. Consistent with this, we found significant variation among the subjects’ isolates, predominantly in the N-terminal half of the protein. Similarly, most HSV-1 gE sequences contained numerous amino acid substitutions relative to gE of KOS. Though our sample size was small, no consistent differences were readily apparent between sequences derived from infected gD-2 vaccine recipients and control recipients. In contrast, the HSV-2 gC and gE sequences we determined remained relatively uniform. The S123F substitution was previously observed in 4 of 5 HSV-2 gC genes sequenced [82], in a background of similarly low nucleotide and amino acid variation. The one exception was a highly polymorphic HSV-2 gC from a control recipient (Fig 2B). The higher affinity of HSV-2 gC for C3b binding than HSV-1 gC [83] may constrain its sequence variation if prevention of complement-mediated lysis is especially important to HSV-2 success. Whether subtle conformational alterations in HSV-1 gC and/or gE change the degree to which gD on the virion is shielded from antibody binding [25] remains to be determined, but our data thus far do not support the hypothesis that viruses infecting vaccine recipients were successful because of alterations in these glycoproteins.

HSV-2 gB is more variable than HSV-2 gD, as was previously found in another study of HIV-1/HSV-2 co-infected individuals [29]. In that study, HSV-2 gD amino acid sequences contained no or only 1 amino acid substitution (with 0 to 3 nucleotide changes), whereas gB sequences varied by an average of 2 to 7 amino acids per strain (and 4 to 10 nucleotides), a level of variation equivalent to what we observed (Fig 3B). The higher affinity of HSV-2 gC for C3b binding than HSV-1 gC [83] may constrain its sequence variation if prevention of complement-mediated lysis is especially important to HSV-2 success. Whether subtle conformational alterations in HSV-1 gC and/or gE change the degree to which gD on the virion is shielded from antibody binding [25] remains to be determined, but our data thus far do not support the hypothesis that viruses infecting vaccine recipients were successful because of alterations in these glycoproteins.

HSV-2 gB is more variable than HSV-2 gD, as was previously found in another study of HIV-1/HSV-2 co-infected individuals [29]. In that study, HSV-2 gD amino acid sequences contained no or only 1 amino acid substitution (with 0 to 3 nucleotide changes), whereas gB sequences varied by an average of 2 to 7 amino acids per strain (and 4 to 10 nucleotides), a level of variation equivalent to what we observed (Fig 3B). The higher affinity of HSV-2 gC for C3b binding than HSV-1 gC [83] may constrain its sequence variation if prevention of complement-mediated lysis is especially important to HSV-2 success. Whether subtle conformational alterations in HSV-1 gC and/or gE change the degree to which gD on the virion is shielded from antibody binding [25] remains to be determined, but our data thus far do not support the hypothesis that viruses infecting vaccine recipients were successful because of alterations in these glycoproteins.
response, though whether that includes a vaccine-induced response to gD alone is still a matter of conjecture worthy of further exploration. Knowledge of inter-strain variations in gB and other viral proteins will permit refinement of vaccine antigens to generate a robust and broadly cross-reactive immune response.

Our sets of gD sequences from the Herpevac Trial dramatically increase the total number of gD sequences available for HSV-1 and HSV-2 primary isolates, particularly those from North America. HSV-2 gC sequences obtained in this study double the total number available for analysis, and the HSV-2 gE sequences represent the first from North American primary isolates. The fact that so many of the primary isolate glycoprotein sequences currently deposited in GenBank derive from other continents (Europe, Africa and Asia) may contribute to the different frequencies of polymorphic nucleotides in HSV-1 gD and gE when compared with the sequences in our study (Table 3) because we used reference sequence HSV-1 KOS (a U.S. strain). It is also possible, however, that the immune response to gD-2 vaccine may have subtly constrained the variation in wild-type HSV-1 strains able to successfully infect Herpevac Trial participants. Some Ts/Tv ratios were lower or higher than the expected range of 2 to 3 for coding regions of human genes [89], deviations previously observed for select HSV genes [27,49,90]. Because twice as many transversions as transitions are possible, a lower Ts/Tv ratio implies greater probability of transversional substitution even though high G+C content of HSV genes and hypermethylation of CpG dinucleotides would bias toward an elevated transition rate. Codon usage bias [91] and activities of DNA glycosylase and other mismatch repair enzymes may also influence the ratio.

In summary, gD sequence variation was highly constrained. Although numerous amino acid changes occurred in gC, gE, and gB relative to the reference sequences, especially for HSV-1, no consistent changes were identified that could be a correlate of successful infection. Comparison of ADCC activity or neutralizing antibody target(s) against viruses with glycoprotein variants, and in vaccinated infected subjects versus infected control recipients, may provide insights to guide further development of herpes simplex vaccines.

Supporting information

S1 Table. Genomes and accession numbers. (DOCX)

S2 Table. Ratio of non-synonymous to synonymous evolutionary substitutions (dN/dS ratio) within the US27 (gB), UL44 (gC), US6 (gD) and US8 (gE) genes for all HSV-1 and -2 strains sampled. (DOCX)

S3 Table. Amino acid positions under selection for HSV-1 and HSV-2 using five methods of analysis. (DOCX)

Acknowledgments

We thank Tammy Blevins, Michelle Mitchel, Tara Giebe, and Yinyi Yu for technical assistance. This work was funded by National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases, Option 10E-12-0106 to RBB.

Author Contributions

Conceptualization: RBB LAM.
Data curation: MAM MK HW LAM.
Formal analysis: MAM LAM.
Funding acquisition: RBB.
Investigation: MAM MK HW LAM.
Methodology: MAM MK.
Project administration: LAM.
Supervision: RBB LAM.
Validation: MAM LAM.
Visualization: MAM MK LAM.
Writing – original draft: LAM.
Writing – review & editing: MAM RBB LAM.

References
1. Roizman B, D.M. K, Whitley RJ (2013) Herpes Simplex Viruses. In: Knipe DM, Howley PM, editors. Fields Virology. 6 ed. Fields Virology: Lippincott Williams & Wilkins. pp. 1823–1897.
2. Bernstein DI, Bellamy AR, Hook EW 3rd, Levin MJ, Wald A, et al. (2013) Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 56: 344–351. https://doi.org/10.1093/cid/cis891 PMID: 23087395
3. Bhattarakosol P, Visaprom S, Sangdara A, Mungmee V (2005) Increase of genital HSV-1 and mixed HSV-1 and HSV-2 infection in Bangkok, Thailand. J Med Assoc Thai 88 Suppl 4: S300–304.
4. Gilbert M, Li X, Petric M, Krajden M, Isaac-Renton JL, et al. (2011) Using centralized laboratory data to monitor trends in herpes simplex virus type 1 and 2 infection in British Columbia and the changing etiology of genital herpes. Can J Public Health 102: 225–229. PMID: 21714324
5. Kortekangas-Savolainen O, Vuorinen T (2007) Trends in herpes simplex virus type 1 and 2 infections among patients diagnosed with genital herpes in a Finnish sexually transmitted disease clinic, 1994–2002. Sex Transm Dis 34: 37–40. https://doi.org/10.1097/01.olq.0000227258.10451.62 PMID: 17195754
6. Ryder N, Jin F, McNulley AM, Grulich AE, Donovan B (2009) Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and young men who have sex with men, 1992–2006. Sex Transm Infect 85: 416–419. https://doi.org/10.1136/sti.2008.033902 PMID: 19273479
7. Samra Z, Scherf E, Dan M (2003) Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel. Sex Transm Dis 30: 794–796. https://doi.org/10.1097/01.olq.0000079517.04451.79 PMID: 14520180
8. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, et al. (2015) Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 10: e114989. https://doi.org/10.1371/journal.pone.0114989 PMID: 25608026
9. Pinninti SG, Kimberlin DW (2013) Neonatal herpes simplex virus infections. Pediatr Clin North Am 60: 351–365. https://doi.org/10.1016/j.pcl.2012.12.005 PMID: 23481105
10. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr., et al. (2008) Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 3: e2230. https://doi.org/10.1371/journal.pone.0002230 PMID: 18493817
11. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73–83. PMID: 16327322
12. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, et al. (1998) Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280: 61–66. PMID: 9660365
13. Gray RH, Li X, Wawer MJ, Serwadda D, Sewankambo NK, et al. (2004) Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 189: 1209–1215. https://doi.org/10.1086/382750 PMID: 15031789
14. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, et al. (2012) Herpes virus fusion and entry: a story with many characters. Viruses 4: 800–832. https://doi.org/10.3390/v4050800 PMID: 22754650

15. Heldwein EE, Krummenacher C (2008) Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 65: 1653–1668. https://doi.org/10.1007/s00018-008-7570-z PMID: 18351291

16. Atanasiu D, Saw WT, Cohen GH, Eisenberg RJ (2010) Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol 84: 12292–12299. https://doi.org/10.1128/JVI.01700-10 PMID: 20861251

17. Atanasiu D, Whitbeck JC, de Leon MP, Lou H, Hannah BP, et al. (2010) Bimolecular complementation defines functional regions of Herpes simplex virus gD that are involved with gH/gL as a necessary step leading to cell fusion. J Virol 84: 3825–3834. https://doi.org/10.1128/JVI.02687-09 PMID: 20130048

18. Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T (2012) Viral and cellular contributions to herpes simplex virus entry into the cell. Curr Opin Virol 2: 28–36. https://doi.org/10.1016/j.coviro.2011.12.001 PMID: 22440963

19. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB (1984) Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 309: 633–635. PMID: 6328323

20. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, et al. (1986) Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol 137: 1636–1641. PMID: 3018078

21. Dubin G, Socolof E, Frank I, Friedman HM (1991) Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol 65: 7046–7050. PMID: 1658396

22. Frank I, Friedman HM (1989) A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 63: 4479–4488. PMID: 2552134

23. Johnson DC, Feenstra V (1987) Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with Fc and binds immunoglobulin. J Virol 61: 2208–2216. PMID: 3035221

24. Ndjamen B, Farley AH, Lee T, Fraser SE, Bjorkman PJ (2014) The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface. PLoS Pathog 10: e1003961. https://doi.org/10.1371/journal.ppat.1003961 PMID: 24604090

25. Rose L, Crowley B (2013) Molecular characterization of clinical isolates of herpes simplex virus type 1 collected in a tertiary-care hospital in Dublin, Ireland. J Med Virol 85: 839–844. https://doi.org/10.1002/jmv.23541 PMID: 23508909

26. Szpara ML, Gatherer D, Ochoa A, Greenbaum B, Dolan A, et al. (2014) Evolution and diversity in human herpes simplex virus genomes. J Virol 88: 1209–1227. https://doi.org/10.1128/JVI.01987-13 PMID: 24227835

27. Lamers SL, Newman RM, Laeyendecker O, Tobian AA, Colgrove RC, et al. (2015) Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. J Virol 89: 8206–8218. https://doi.org/10.1128/JVI.01302-15 PMID: 26018161

28. Abrao EP, Burrel S, Desire N, Bonnafous P, Godet A, et al. (2015) Impact of HIV-1 infection on herpes simplex virus type 2 genetic variability among co-infected individuals. J Med Virol 87: 357–365. https://doi.org/10.1002/jmv.24061 PMID: 25174847

29. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652–1661. https://doi.org/10.1056/NEJMoai011915 PMID: 12444179

30. Belshé RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34–43. https://doi.org/10.1056/NEJMoai1103151 PMID: 22216840

31. Belshé RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, et al. (2014) Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 209: 828–836. https://doi.org/10.1093/infdis/jit651 PMID: 24285844

32. Cohen GH, Dietzschold B, Ponce de Leon M, Long D, Golub E, et al. (1984) Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J Virol 49: 102–108. PMID: 6197535

33. Chiang HY, Cohen GH, Eisenberg RJ (1994) Identification of functional regions of herpes simplex virus glycoprotein gD by using linker-insertion mutagenesis. J Virol 68: 2529–2543. PMID: 7511173
35. Connolly SA, Landsburg DJ, Carfi A, Wiley DC, Cohen GH, et al. (2003) Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol 77: 8127–8140. https://doi.org/10.1128/JVI.77.14.8127-8140.2003 PMID: 12829851

36. Lee CC, Lin LL, Chan WE, Ko TP, Lai JS, et al. (2013) Structural basis for the antibody neutralization of herpes simplex virus. Acta Crystallogr D Biol Crystallogr 69: 1935–1945. https://doi.org/10.1107/S0907444913016776 PMID: 24100313

37. Lazear E, Whitbeck JC, Ponce-de-Leon M, Cairns TM, Willis SH, et al. (2012) Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. J Virol 86: 1563–1576. https://doi.org/10.1128/JVI.06480-11 PMID: 22130533

38. Whitbeck JC, Huang ZY, Cairns TM, Gallagher JR, Lou H, et al. (2014) Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D. J Virol 88: 7786–7795. https://doi.org/10.1128/JVI.00544-14 PMID: 24789783

39. Morrison LA, Knipe DM (1996) Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology 220: 402–413. https://doi.org/10.1006/viro.1996.0328 PMID: 8661391

40. Kumar SD, Stecher G, Tamura K (2016) MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol 33: 1870–1874. https://doi.org/10.1093/molbev/msw054 PMID: 27004904

41. Smith KO (1964) Relationship between the envelope and the infectivity of herpes simplex virus. Proc Soc Exp Biol Med 115: 814–816. PMID: 14155835

42. Ejercito PM, Kieff ED, Roizman B (1968) Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol 2: 357–364. https://doi.org/10.1099/0022-1317-2-3-357 PMID: 4300104

43. Colgrove R, Diaz F, Newman R, Salf S, Shea T, et al. (2014) Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain. Virology 450–451: 140–145. https://doi.org/10.1016/j.viro.2013.12.014 PMID: 24503076

44. Brown SM, Ritchie DA, Subak-Sharpe JH (1973) Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J Gen Virol 18: 329–346. https://doi.org/10.1099/0022-1317-18-3-329 PMID: 4348796

45. Williams LE, Nesburn AB, Kaufman HE (1965) Experimental induction of disciform keratitis. Arch Ophthalmol 73: 112–114. PMID: 14223669

46. Rawls WE, Laurel D, Melnick JL, Glicksman JM, Kaufman RH (1968) A search for viruses in smegma, premalignant and early malignant cervical tissues. The isolation of Herpesviruses with distinct antigenic properties. Am J Epidemiol 87: 647–655. PMID: 5694774

47. Duff R, Rapp F (1971) Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nat New Biol 233: 48–50. PMID: 4329350

48. L. SD (2003) PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4b10. Sinauer Associates. Sunderland, Massachusetts, USA.

49. Kumar SD, A.; Singh A. (2011) Substitution model analysis of human herpes simplex virus using molecular evolutionary genetic analysis. Biotechnol Bioinf Bioeng 1: 451–458.

50. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, et al. (2017) GenBank. Nucleic Acids Res 45: D37–D42. https://doi.org/10.1093/nar/gkw1070 PMID: 27899564

51. Korsakov SL, Frost SD, Grossman Z, Gravenor MB, Richman DD, et al. (2006) Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol 2: e62. https://doi.org/10.1371/journal.pcbi.0020062 PMID: 16789820
57. Murrell B, Wertheim JO, Moola S, Weighill T, Scheffler K, et al. (2012) Detecting individual sites subject to episodic diversifying selection. PLoS Genet 8: e1002764. https://doi.org/10.1371/journal.pgen.1002764 PMID: 22807683

58. Murrell B, Moola S, Mabona A, Weighill T, Sheward D, et al. (2013) FUBAR: a fast, unconstrained bayesian approximation for inferring selection. Mol Biol Evol 30: 1196–1205. https://doi.org/10.1093/molbev/mst030 PMID: 23420840

59. Haarr L, Nilsen A, Knappskog PM, Langeland N (2014) Stability of glycoprotein gene sequences of herpes simplex virus type 2 from primary to recurrent human infection, and diversity of the sequences among patients attending an STD clinic. BMC Infect Dis 14: 63. https://doi.org/10.1186/1471-2334-14-63 PMID: 24502528

60. Atanasiu D, Whitbeck JC, Cairns TM, Reilly B, Cohen GH, et al. (2007) Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A 104: 18718–18723. https://doi.org/10.1073/pnas.0704752104 PMID: 18003913

61. Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NF receptor family. Cell 87: 427–436. PMID: 8898196

62. Kwon BS, Tan KB, Ni J, Oh KO, Lee ZH, et al. (1997) A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 272: 14272–14276. PMID: 9152661

63. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG (1998) Entry of alphaherpesviruses mediated by poxvirus receptor-related protein 1 and poxvirus receptor. Science 280: 1618–1620. PMID: 9616127

64. Takahashi K, Nakashita H, Miyahara M, Mandal K, Satoh K, et al. (1999) Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol 145: 539–549. PMID: 10225955

65. Shukla D, Liu J, Blaklock P, Shworaik NW, Baxi X, et al. (1999) A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99: 13–22. PMID: 10520990

66. Warner MS, Geraghty RJ, Martinez WM, Montgomery RI, Whitbeck JC, et al. (1998) A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 246: 179–189. https://doi.org/10.1006/viro.1998.9218 PMID: 9657005

67. Lazear E, Carli A, Whitbeck JC, Cairns TM, Krummenacher C, et al. (2008) Engineered disulfide bonds in herpes simplex virus type 1 gD separate receptor binding from fusion initiation and viral entry. J Virol 82: 700–709. https://doi.org/10.1128/JVI.02192-07 PMID: 18032483

68. Gallagher JR, Saw WT, Atanasiu D, Lou H, Eisenberg RJ, et al. (2013) Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD. J Virol 87: 12656–12666. https://doi.org/10.1128/JVI.01727-13 PMID: 24049165

69. Carli A, Willis SH, Whitbeck JC, Krummenacher C, Cohen GH, et al. (2001) Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell 8: 169–179. PMID: 11511370

70. Di Giovine P, Settembre EC, Bhargava AK, Luftig MA, Lou H, et al. (2011) Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog 7: e1002277. https://doi.org/10.1371/journal.ppat.1002277 PMID: 21980294

71. Fan Q, Longnecker R, Connolly SA (2014) Substitution of herpes simplex virus 1 entry glycoproteins with those of saimiri herpesvirus 1 reveals a gD-gH/gL functional interaction and a region within the gD profusion domain that is critical for fusion. J Virol 88: 6470–6482. https://doi.org/10.1128/JVI.00465-14 PMID: 24672037

72. Gianni T, Amasio M, Campadelli-Fiume G (2009) Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. J Biol Chem 284: 17370–17382. https://doi.org/10.1074/jbc.M109.005728 PMID: 19386594

73. Cairns TM, Huang ZY, Gallagher JR, Lin Y, Lou H, et al. (2015) Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific. J Virol 89: 9213–9231. https://doi.org/10.1128/JVI.01213-15 PMID: 26109729

74. Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, et al. (2014) Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J Virol 88: 12612–12622. https://doi.org/10.1128/JVI.01930-14 PMID: 25142599

75. Chentoufi AA, Zhang X, Lambeth K, Dasgupta G, Bettahi I, et al. (2008) HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 180: 426–437. PMID: 18097044
76. Zhang X, Castelli FA, Zhu X, Wu M, Mailiere B, et al. (2008) Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vaccine Immunol 15: 1436–1449. https://doi.org/10.1128/CVI.00123-08 PMID: 18667634

77. Newman RM, Lamers SL, Weiner B, Ray SC, Colgrove RC, et al. (2015) Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol 89: 8219–8232. https://doi.org/10.1128/JVI.01303-15 PMID: 26018166

78. Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM (2011) Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 203: 1434–1441. https://doi.org/10.1093/infdis/jir047 PMID: 21498376

79. Sakaoka H, Kawata T, Grillner L, Aomori T, Yamaguchi T, et al. (1987) Genome variations in herpes simplex virus type 2 strains isolated in Japan and Sweden. J Gen Virol 68 (Pt 8): 2105–2116.

80. Sakaoka H, Saito H, Sekine K, Aomori T, Grillner L, et al. (1987) Genomic comparison of herpes simplex virus type 1 isolates from Japan, Sweden and Kenya. J Gen Virol 68 (Pt 3): 749–764.

81. Norberg P, Kasubi MJ, Haarr L, Bergstrom T, Liljegqvist JA (2007) Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 81: 13158–13167. https://doi.org/10.1128/JVI.01310-07 PMID: 17881457

82. Terhune SS, Coleman KT, Sekulovich R, Burke RL, Spear PG (1998) Limited variability of glycoprotein gene sequences and neutralizing targets in herpes simplex virus type 2 isolates and stability on passage in cell culture. J Infect Dis 178: 8–15. PMID: 9652417

83. Rux AH, Lou H, Lambris JD, Friedman HM, Eisenberg RJ, et al. (2002) Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. Virology 294: 324–332. https://doi.org/10.1006/viro.2001.1326 PMID: 12009874

84. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, et al. (2006) Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313: 217–220. https://doi.org/10.1126/science.1126548 PMID: 16840698

85. Stamper SD, Lou H, Cohen GH, Eisenberg RJ, Heldwein EE (2010) Structural basis of local, pH-dependent conformational changes in glycoprotein B from herpes simplex virus type 1. J Virol 84: 12924–12933. https://doi.org/10.1128/JVI.01750-10 PMID: 20943984

86. Bender FC, Samanta M, Heldwein EE, de Leon MP, Bilman E, et al. (2007) Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol 81: 3827–3841. https://doi.org/10.1128/JVI.02710-06 PMID: 17267495

87. Cairns TM, Fontana J, Huang ZY, Whitbeck JC, Atanasiu D, et al. (2014) Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B. J Virol 88: 2677–2689. https://doi.org/10.1128/JVI.03200-13 PMID: 24352457

88. Gallagher JR, Atanasiu D, Saw WT, Paradisgarten MJ, Whitbeck JC, et al. (2014) Functional fluorescent protein insertions in herpes simplex virus gB report on gB conformation before and after execution of membrane fusion. PLoS Pathog 10: e1004373. https://doi.org/10.1371/journal.ppat.1004373 PMID: 25233449

89. Zhang Z, Gerstein M (2003) Patterns of nucleotide substitution, insertion and deletion in the human genome inferred from pseudogenes. Nucleic Acids Res 31: 5338–5348. https://doi.org/10.1093/nar/gkg745 PMID: 12954770

90. Khrustalev VV, Barkovsky EV (2009) Mutational pressure is a cause of inter- and intragenomic differences in GC-content of simplex and varicello viruses. Comput Biol Chem 33: 295–302. https://doi.org/10.1016/j.compbiolchem.2009.06.005 PMID: 19617003

91. Keller I, Bensasson D, Nichols RA (2007) Transition-transversion bias is not universal: a counter example from grasshopper pseudogenes. PLoS Genet 3: e22. https://doi.org/10.1371/journal.pgen.0030022 PMID: 17274688